Your browser doesn't support javascript.
loading
Severely complicated ear infection in a patient treated with ixekizumab: a case report.
Maertens, Léonore; Pollet, Naomi; Clarysse, Marta; Vanderbeke, Lore; Verhaert, Nicolas; Desloovere, Christian; Loos, Elke.
Affiliation
  • Maertens L; Department of Otorhinolaryngology-Head and Neck Surgery, ENT Resident, University Hospitals Leuven, Leuven, 3000, Belgium. leonore.maertens@gmail.com.
  • Pollet N; Department of Otorhinolaryngology-Head and Neck Surgery, ENT Resident, University Hospitals Leuven, Leuven, 3000, Belgium.
  • Clarysse M; Department of Otorhinolaryngology-Head and Neck Surgery, ENT Resident, University Hospitals Leuven, Leuven, 3000, Belgium.
  • Vanderbeke L; Internal Medicine Department, University Hospitals Leuven, Leuven, 3000, Belgium.
  • Verhaert N; Department of Otorhinolaryngology-Head and Neck Surgery, ENT Resident, University Hospitals Leuven, Leuven, 3000, Belgium.
  • Desloovere C; Department of Neurosciences, Research Group Experimental Oto-Rhino-Laryngology (ExpORL), KU Leuven, University of Leuven, Leuven, 3000, Belgium.
  • Loos E; Department of Otorhinolaryngology-Head and Neck Surgery, ENT Resident, University Hospitals Leuven, Leuven, 3000, Belgium.
Article in En | MEDLINE | ID: mdl-38977473
ABSTRACT
We report a case of a severe ear infection in a 35-year-old man treated with ixekizumab for psoriasis. Ixekizumab is a humanized monoclonal antibody that selectively prevents the interaction between interleukin 17 A and its receptor. Biologicals like ixekizumab are used to achieve symptom relief in autoimmune diseases including psoriasis. Unlike the mild upper respiratory tract infections usually described as side-effects of this treatment, we report a case of a patient who presented with a severe otitis media, complicated with a facial paresis and nasopharyngeal abscess. To the best of our knowledge, this is the first case presenting a severe, complicated ear infection as a possible side effect of ixekizumab. We conclude that when using ixekizumab, vigilance for upper airway infections is needed and if necessary, interruption of therapy should be considered. However, further research is needed to confirm this hypothesis.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Eur Arch Otorhinolaryngol Journal subject: OTORRINOLARINGOLOGIA Year: 2024 Document type: Article Affiliation country: Bélgica

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Eur Arch Otorhinolaryngol Journal subject: OTORRINOLARINGOLOGIA Year: 2024 Document type: Article Affiliation country: Bélgica